Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 43

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
7,019 Commercial notes— 26,449 — 26,449 Corporate debt securities— 515,234 — 515,234 Total available-for-sale securities— 770,579 — 770,579 Cash equivalentsMoney market instruments81,283 — — 81,283 Term deposit— 11,049 — 11,049 U.S. Treasuries— 7,960 — 7,960 Commercial notes— 23,770 — 23,770 Total cash equivalents81,283 42,779 — 124,062 Total financial assets$81,283 $813,358 $— $894,641 September 30, 2024Level 1Level 2Level 3Total(in thousands)Available-for-sale securitiesU.S. government and agency securities$— $160,723 $— $160,723 Commercial notes— 179,714 — 179,714 Corporate debt securities— 237,839 — 237,839 Total available-for-sale securities— 578,276 — 578,276 Cash equivalentsMoney market instruments66,966 — — 66,966 Total cash equivalents66,966 — — 66,966 Total financial assets$66,966 $578,276 $— $645,242 

21

NOTE 11. LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES

In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0 million in cash to the Company in consideration for the Company’s future royalty interest in olpasiran, originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0 million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0 million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization